Skip to content
Contact
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Medical Education
  • Programs
    • Epigenetics
    • Pipeline
    • Publications
  • Medicines
  • Collaborations
  • Clinical Trials
  • Investor Center
    • Investor Center
    • Press Releases
    • Events & Presentations
    • Publications
    • Stock Information
    • SEC Filings
    • Annual Meeting
    • Financial Information
    • Corporate Governance
    • Analyst Coverage
    • Investor FAQs
    • Contact Us
  • Careers

ASH 2015

ASH 2015

Epizyme scientists and clinician collaborators presented the following work at the 2015 ASH conference in Orlando, Florida. (Files are in .pdf format)

  • Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor Pinometostat (EPZ-5676) in Children with MLL-r Acute Leukemia: Safety, Exposure and Evidence of Target Inhibition

  • A Phase 1 Study of the DOT1L Inhibitor Pinometostat (EPZ-5676) in Advanced Leukemia: Safety, Activity and Evidence of Target Inhibition

  • Home
  • Privacy Policy
  • Terms of Use
  • Site Map
  • Contact
© 2020 Epizyme, Inc. - All Rights Reserved
▲